- Nanotechnologies, Advanced Materials, Advanced Manufacturing and Processing, and Biotechnology
Developing innovative nanomedical products for a more personalized, predictive and efficient medicine requires further integration of nanotechnologies aiming at applications in human health notably with further Key Enabling Technologies. It also needs a functioning ecosystem of actors, in which the research, translation, regulation, standardization and take-up of innovative nanomedicines by the different European healthcare systems is stimulated. End-of-life/disposal and recyclability issues should also be addressed as appropriate.
Supporting the development of an ecosystem for nanomedicine in Europe, including activities such as coordinating national platforms and regional clusters; developing common training material and services; international cooperation related to community building, road-mapping, regulation, manufacturing, reimbursement and pricing, standardization and recyclability; and reaching out to attract the interest of citizens, young talents and young entrepreneurs. Collaborations with relevant technology platforms or similar initiatives in Europe or worldwide will allow deeper and more effective cross-KETs activities for innovative integrated solution and well as a consolidated international strategy for the sector.
Attention should be paid to achieve a cross-regional, cross-sectoral and cross-technological approach, based on the analysis of relevant roadmaps, strategic research agendas or smart specialisation strategies which have listed nanomedicine or personalised Medicine as one of their priorities. These different approaches might for instance be united into one “meta” roadmap.
The Commission considers that proposals requesting a contribution from the EU between EUR 1 and 2 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.
- Increased take-up of innovative Nanomedicine solutions by industry and SMEs, end-users, regulatory and public authorities, healthcare insurances, doctors and patients, research organisations and academia;
- Improvement of cross-KETs activities to provide better integrated healthcare solutions;
- Increased international networking with new potential market opportunities;
- Improvement of the competitiveness of the European healthcare sector.